RxDoctor Payments Data

Benjamin Papoi, DO

Family Medicine · Damascus, MDNPI 1750374492

Payments from drug & device makers

$208in general payments, 2019–2025

Across 12 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$75
  • Lilly USA, LLC$46
  • Boehringer Ingelheim$30
  • Aerin Medical Inc.$27
  • Medtronic$19
  • Novo Nordisk$11

What the payments were for

  • Food & beverage$16680%
  • Education$4220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)4$75
Lilly USA, LLC3$46
Boehringer Ingelheim2$30
Aerin Medical Inc.1$27
Medtronic1$19
Novo Nordisk1$11

How this compares

$208 in reported general payments places this provider in the 40th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$511,293
Medicare patients
1,140
Services billed
5,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$109,731
EliquisApixaban54$60,353
XareltoRivaroxaban27$45,234
JanuviaSitagliptin Phosphate26$37,784
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$36,130
Tresiba Flextouch U-200Insulin Degludec16$35,838
JardianceEmpagliflozin18$30,658
TrulicityDulaglutide14$28,795
TradjentaLinagliptin27$25,646
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$20,320
RybelsusSemaglutide12$16,335
EntrestoSacubitril/Valsartan11$16,255
MyrbetriqMirabegron22$13,187
SynthroidLevothyroxine Sodium110$9,087
Atorvastatin Calcium346$6,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$11$126,06692 claims
Boehringer IngelheimJardiance, Tradjenta$30$56,30445 claims
Lilly USA, LLCTrulicity$46$28,79514 claims
AbbVieSynthroid$75$9,087110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Damascus

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →